Medical Industry News Archive

Click here to search our archive

Print using browser

URGENT MEDICINE RECALL: SANDOZ CEFPODOXIME 40mg/5ml Reg No A39/20.1.1/0397 (50ml and 100ml pack sizes)
Sandoz SA (Pty) Ltd in collaboration with the Medicines Control Council are initiating a Class 2, Type B recall on all batches of Sandoz Cefpodoxime 40mg /5ml (50ml and 100ml pack sizes).

Sandoz Cefpodoxime 40mg/5ml powder for oral suspension is an antibiotic used for short- term treatment of lower and upper respiratory tract infections in infants, children and adults.

The product is being recalled due to lower than expected efficacy, high unknown impurities, discolouration and formation of brownish agglomerates on certain batches of Sandoz Cefpodoxime 40mg/5ml tested during stability monitoring.

Use of the product may lead to weakened patient therapy through insufficient anti-infective treatment resulting in: a patient being contagious to others for a longer time, the development and spread of resistant bacterial strains, and significant therapeutic difficulties in eradication of respective bacteria.

In the interest of patient safety, Sandoz SA (Pty) Ltd request that you immediately return all batches of Sandoz Cefpodoxime 40mg/5ml stock without delay to your supplying wholesaler or distributor for full credit.
Sandoz SA (Pty) Ltd would like to thank you for your co-operation and apologise for any inconvenience caused.

Should you have any enquiries in this regard kindly contact the Sandoz Customer Call Centre 0861 SANCAL or 0861 726 225 during office hours and a technical support 24 hour call no 0768114744.

For full prescribing information please refer to package insert approved by Medical Regulatory Authority

Sandoz SA (Pty) Ltd PO Box 154, Isando 1600 Kempton Park, Gauteng South Africa Tel Fax +27 (0) 11 394 3084    Reg No: 1990/001979/07
Directors: R-A Bassoul (Canadian) J-C Dubos (French) M.M Paleja (Singaporean)  
A Novartis Company

You need to be logged in to see more details. Register Now!

Click here for more information .....
Contact: Carla Urbani-Smith, (Responsible Pharmacist)
Telephone: +27 (0) 11 929 9000
Date: Tuesday, February 14, 2012

Archive News Headlines
Watson Pharma (Pty) Ltd change their name to Actavis
Pfizer discontinue Kessar 10mg tablets (Tamoxifen Citrate)
Boehringer Ingelheim discontinue Gericomplex capsules 30's (Dimethylaminoethanol Bitatrate)
Pfizer - Stock Shortage - Valoron 50mg/ 5ml Drops 10ml (tilidine hydrochloride semi-hydrate)
Ranbaxy - Stock shortage - Diolo 80 and Diolo 160 (valsartan)
Takeda - Stock Shortage - Theoplus 200mg tablets (theophylline, anhydrous)
Aspen - Stock Availability - Tenarenz film-coated tablets (tenofovir disoproxil fumarate, lamivudine and efavirenz)
Janssen Pharmaceutica discontinue Jurnista 8mg 14's (hydromorphone)
Adcock - Stock Outage - Serez 25mg, 100mg, 200mg & 300mg Tablets (Quetiapine)
Aspen - Stock Shortage - Macrodantin 50 mg Capsules (nitrofurantoin)
Cipla - Stock Availability - Duolin Respules (Ipratropium bromide monohydrate and Salbutamol sulphate)
Cipla - Stock Availability - Budeflam DP Capsules (Budesonide 200 µg)
Aspen - Changes to Normison 10 mg capsules (temazepam)
Cipla discontinue Ciplazar Co 50/12.5 and Ciplazar Co 100/25 mg (Losartan/ Hydrochlorothiazide 50/12,5mg or 100/25mg)
Cipla discontinue Preflam Syrup (Prednisolone)
AstraZeneca Pharmaceuticals and Aspen launch Trustan (esomeprazole) 20 mg & 40 mg tablets
Watson Pharma - Stock Availability - Amoclan BID tablets (Amoxicillin/Clavulanate)
Ranbaxy - Stock shortage - Simvotin 40mg 28’s (simvastatin)